fashion -WSS

fashion

author：knowledge 2025-09-29 21:26:40 - browse：99

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： ProMED, early warning system on disease outbreaks, in peril

WSS

2 US Navy sailors arrested for allegedly spying for China

Dramatically reducing cancer deaths requires the PASTEUR Act

Biogen nominates mother of director’s child to replace him on board

Reanimated hearts work just as well for transplants, study finds

Mom launches Girl Scout troop for LGBTQ youth in Texas

Gilgo Beach: Police identify another victim in serial killing investigation

hotspot

fashion

focus

Walensky prepares to leave CDC — and Congress — behind

What the cancer research community can learn from the Covid response

Hollywood unions extend contract negotiations for actors

The drug industry sees a key ally in the Senate prevail

Medical leaders decry Supreme Court decision on affirmative action

My superpower is killing ticks

Apple is now the first public company to be valued at $3 trillion

Stem cell clinics for heart failure: buyer be wary

Bright Health sells Medicare Advantage business to Molina

What the cancer research community can learn from the Covid response

entertainment

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

Dramatically reducing cancer deaths requires the PASTEUR Act

Biogen nominates mother of director’s child to replace him on board

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

Sea level rise could wash away turtle breeding grounds around the world, researchers say

For BCIs, commercial hurdles may be bigger than scientific ones

focus

entertainment

hotspot

entertainment